Description: Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Home Page: onconetix.gcs-web.com
201 East Fifth Street
Cincinnati,
OH
45202
United States
Phone:
513 620 4101
Officers
| Name | Title |
|---|---|
| Dr. Ralph Schiess Ph.D. | Interim CEO & Chief Science Officer |
| Ms. Karina M. Fedasz | Interim Chief Financial Officer |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Mr. Frank A. Jaeger M.A., M.B.A. | Senior VP of Marketing & Business Development |
| Mr. Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Mr. Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science & Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Mr. Christian Bruhlmann | Chief Strategy Officer & GM of Europe |
| Dr. Donald L. Very Jr., Ph.D. | Senior VP of Commercial Research & Development |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3252 |
| Price-to-Sales TTM: | 0.0443 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |